Geneos Therapeutics Stock

Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.

Sign up today and learn more about Geneos Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Geneos Therapeutics Stock

Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease.

Funding History

February 2019$10.5M
March 2021$12.0M
March 2022$17.0M
April 2023$5.0M

Management

Founder, President & CEO, Director

Niranjan Y. Sardesai

Vice President, Head of Operations and Business Development

James A. Barlow

Board Member

Sangwoo Lee

Board Member

J. Joseph Kim

Board Member

Ted Fjällman

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo